ClinicalTrials.gg
RecruitingNCT02523014Updated Nov 3, 2026

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

A Phase 2 interventional study of Vismodegib and FAK Inhibitor GSK2256098 in Intracranial Meningioma, Recurrent Meningioma and NF2 Gene Mutation, sponsored by Alliance for Clinical Trials in Oncology. Recruiting at 791 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-03.

Sponsored by Alliance for Clinical Trials in Oncology · Phase 2, Interventional, and Treatment

How we know · 9 judgments

From the registry’s dates

  • Started Sep 2015; still recruiting 11 years 1 month later.
Updated Nov 3, 2026Site recruiting status changedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
124
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 129 studies in Meningioma with a site in United States — 27 open to participants now, 39 under way, 1 of them phase 3. Meningioma · United States.

Planned enrollment
15th of 107
124 · median 30
Started
2015
with 3 others
Phase 2
46 of 129
10 open now
Primary completion
2028-06
later than 21 of 37 live
Registered
74th of 129
by date

Among the 129 studies in Meningioma with a site in United States, this one is the 15th largest by planned enrollment of the 107 interventional ones that give a count, is one of 4 that started in 2015, is one of 46 in phase 2, reaches primary completion later than 21 of the 37 other live ones, and was the 74th registered.

Meningioma

256 studies on the registry are indexed under Meningioma; 86 are open to participants now.

Browse Meningioma studies →

Open to participants now

27 of the 129 studies in Meningioma with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 66 Meningioma studies recruiting now, 43 (65%) set no upper age limit and 9 (14%) stop at 75 or younger; 8 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 129 studies in Meningioma with a site in United States, or all of them as a file.
02

Study summary

This phase II trial studies how well vismodegib, focal adhesion kinase (FAK) inhibitor GSK2256098, and capivasertib work in treating patients with meningioma that is growing, spreading, or getting worse (progressive). Vismodegib, FAK inhibitor GSK2256098, capivasertib, and abemaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the activity of a SMO inhibitor in patients with meningiomas harboring SMO and PTCH1 mutations as measured by 6-month progression free survival (PFS) and response rate.

II. To determine the activity of a FAK inhibitor in patients with meningiomas harboring NF2 mutations as measured by 6-month PFS and response rate.

III. To determine the activity of an AKT inhibitor in patients with meningiomas harboring AKT1/PIK3CA/PTEN mutations as measured by 6-month PFS and response rate.

IV. To determine the activity of a CDK inhibitor in patients with meningiomas harboring alterations in the CDK pathway or NF2 alterations as measured by 6-month PFS and response rate.

SECONDARY OBJECTIVES:

I. To determine overall survival and progression-free survival of SMO, FAK, AKT and CDK inhibitors in patients with meningioma.

II. To determine adverse event rates of SMO, FAK, AKT and CDK inhibitors in patients with meningioma.

III. To determine the activity of SMO, FAK, AKT and CDK inhibitors as measured by response rate by central radiology review.

OUTLINE: Patients are assigned to 1 of 4 treatment arms based on their mutation status.

ARM A (SMO/PTCH1 mutation): Patients receive vismodegib orally (PO) once daily (QD). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)

ARM B (NF2 mutation): Patients receive FAK inhibitor GSK2256098 PO twice daily (BID). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)

ARM C (AKT1, PIK3CA, or PTEN mutation): Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.

ARM D (CDK4, CDK6, CDKN2A, CCND1, CCND2, CCND3, CCNE1 alterations): Patients receive abemaciclib PO every 12 hours (Q12H). Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up every 6 months for a maximum of 5 years from registration.

03

Conditions studied

  • Intracranial Meningioma
  • Recurrent Meningioma
  • NF2 Gene Mutation

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

  • Documentation of disease:

    • Histologic documentation: proven intracranial meningioma as documented by central pathology review
    • Molecular documentation: Presence of SMO, PTCH1, NF2, CDKN2A, AKT1, PIK3CA, PTEN mutations, CDKN2A copy number loss, CDK4, CDK6, CCND1, CCND2, CCND3, or CCNE1 copy number gain in tumor sample as documented specifically by the central laboratory, regardless of whether prior genotype testing outside of the central laboratory was performed
    • Progressive OR residual disease, as defined by the following:

      • Residual : residual measurable disease immediately after surgery without requirement for progression; for grade I disease, progression pre-operatively needs to be documented, with an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 25 months; for patients with SMO/PTCH1 mutations enrolling to receive vismodegib, the change can occur between scans separated by up to 25 months; residual measurable disease will be defined by bidimensionally measurable lesions with clearly defined margins by MRI scans, with a minimum diameter of 10 mm in both dimensions
      • Progressive measurable disease: progression defined as an increase in size of the measurable primary lesion on imaging by 25% or more (bidirectional area); the change must occur between scans separated by no more than 25 months
      • Post radiation patients: patients with measurable and progressive meningioma who have received radiation are potentially eligible, but need to show evidence of progressive disease after completion of radiation; if the progressive meningioma lesion has been radiated, at least 24 weeks must have elapsed from completion of radiation to registration; if the progressive lesion is outside of the radiation field, then an interval of at least 2 weeks must have elapsed from completion of radiation to registration
  • Measurable disease: measurable disease is defined by a bidimensionally measurable main lesion on MRI or computed tomography (CT) images (MRI preferred) with clearly defined margins and a minimum diameter of 10 mm in both dimensions; multifocal disease is allowed
  • Prior treatment

    • Prior medical therapy is allowed but not required
    • No limit on number of prior therapies
    • No chemotherapy, or other agents within 28 days prior to registration
    • No other concurrent investigational agents or other meningioma-directed therapy (chemotherapy, radiation) while on study; additionally, no cases of nitrosourea or mitomycin C within 6 weeks prior to registration
    • For patients treated with external beam radiation, interstitial brachytherapy or radiosurgery, an interval > 4 weeks must have elapsed from completion of radiation therapy to registration; if the progressive lesion is outside of the radiation field, then an interval of at least 2 weeks must have elapsed from completion of radiation to registration
    • dosing stable for at least 4 days
    • Recovered to (CTCAE) grade 1 or less toxicity from other agents with exception of alopecia and fatigue
    • No craniotomy 28 days prior to and after registration
  • Not pregnant and not nursing:

    * A female of is a sexually mature female who: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally for at least 12 consecutive months (i.e., has had menses at any time in the preceding 12 consecutive months)

  • For patients with NF2/CDKN2A/AKT1/PIK3CA/PTEN mutation, CKDN2A copy number loss, or CDK4/CDK6/CCND1/CCND2/CCND3/CCNE1 copy number gain: Age >= 18 years
  • For patients with SMO/PTCH1 mutation: Age >= 30 years
  • (ECOG) performance status =\< 2
  • Patient history:

    • Patients with history of neurofibromatosis (NF) may have other stable central nervous system (CNS) tumors (schwannoma, acoustic neuroma or ependymoma) if lesions have been stable for 6 months
    • No meningiomas (as defined by extracranial meningiomas outside of CNS) allowed; spinal meningiomas are allowed
    • No history of allergic reactions attributed to compounds of similar or biologic composition to assigned study drug
    • No known active or C
    • No current class B or C liver disease
    • No uncontrolled gastric ulcer disease (grade 3 gastric ulcer disease within 28 days of registration)
    • No uncontrolled hypertension defined as blood pressure (BP) > 140/90
    • No abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 28 days prior to registration
    • No major surgery within 28 days prior to registration for any patients with AKT1/PIK3CA/PTEN mutations receiving capivasertib
    • For patients going on to receive capivasertib (i.e. enrolled after Update #08)

      • Patients should not have any of the following cardiac criteria:

        • Any abnormalities in rhythm, conduction, or morphology of resting (EKG) (e.g., complete left bundle branch block, third degree heart block)
        • Any factors that increase the risk of (QTc) prolongation or risk of arrhythmic events such as heart failure, hypokalemia, potential for Torsade de Pointes, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
        • Experience any of the following procedures or conditions in the preceding 6 months: coronary artery bypass graft, angioplasty, vascular stent, myocardial infarction, angina pectoris, congestive heart failure (NYHA) class >= II
        • Uncontrolled hypertension (systolic blood pressure [SBP] \< 90 mmHg and/or diastolic blood pressure [DBP] \< 50 mmHg)
        • Cardiac outside institutional range of normal or \< 50% (whichever is higher) as measured by echocardiogram (or multigated acquisition [MUGA] scan if an echocardiogram can't be performed or is inconclusive); left ventricular ejection fraction (LVEF) below lower limit of normal for site
      • Patients should not have any of the following criteria:

        • With the exception of alopecia, any unresolved toxicities from prior therapy greater than Common Terminology Criteria for Adverse Events (CTCAE) grade 1 at the time of registration
        • \< 9 g/dL (\< 5.59 mmol/L); note: any blood transfusion must be >= 14 days prior to the determination of a hemoglobin >= 9 g/dL (>= 5.59 mmol/L)
        • Proteinuria 3+ on dipstick analysis or > 500 mg/24 hours
        • nausea and vomiting, chronic gastrointestinal diseases, inability to swallow the formulated product or previous significant bowel resection that would preclude adequate absorption of capivasertib
        • History of to active or inactive of capivasertib or drugs with a similar chemical structure or class to capivasertib
        • Current disease or condition known to interfere with absorption, distribution, metabolism, or excretion of drugs
        • Past medical history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis which required steroid treatment, or any evidence of clinically active interstitial lung disease
        • Previous bone marrow transplant
        • Known immunodeficiency syndrome
  • Concomitant medications (only regarding NF2/CDKN2A/CDK4/CDK6/CCND1/CCND2/CCND3/CCNE1/AKT1/PIK3CA/PTEN genetic alterations):

    • Chronic concomitant treatment with strong inhibitors of cytochrome P450, family 3, subfamily A, polypeptide 4 () inhibitors must discontinue the drug for 14 days prior to registration on the study for patients with NF2 mutation enrolled to GSK2256098, as well as for patients with AKT1/PIK3CA/PTEN mutations enrolled to capivasertib
    • For NF2 patients going on to receive GSK2256098 and for patients with AKT1/PIK3CA/PTEN mutations enrolled to capivasertib: concomitant treatment with strong CYP3A4 inducers or CYP2D6 substrates is not allowed; patients must discontinue the drug 14 days prior to registration
    • For NF2 patients going on to receive abemaciclib: avoid concomitant use of CYP3A inducers and strong CYP3A inhibitors; use caution with coadministered moderate or weak CYP3A inhibitors
  • Diabetic status:

    • For patients with NF2 or SMO/PTCH1 mutations: No uncontrolled diabetes defined as a known diabetic with > 7.5 OR fasting glucose > 140 mg/dL.
    • For patients with AKT1/PIK3CA/PTEN mutations:

      • Glycosylated hemoglobin (HbA1C) \< 8.0% (63.9 mmol/mol)
      • No type 1 diabetes mellitus
      • No requirement for insulin for routine diabetic management and control
      • No requirement for more than two oral hypoglycemic medications for routine diabetic management and control
      • Patients with a pre-existing diagnosis of type 2 diabetes mellitus must have fasting glucose \< 9.3 mmol/L (167mg/dL); fasting is defined as no caloric intake for at least 8 hours
    • Patients without a pre-existing diagnosis of type 2 diabetes mellitus must have fasting glucose =\< 7.0 mmol/L (126 mg/dL); fasting is defined as no caloric intake for at least 8 hours
  • (ANC) >= 1,500/mm\^3
  • count >= 100,000/mm\^3
  • Creatinine OR =\< 1.5 mg/dl x (ULN) OR calculated (calc.) > 50 mL/min
  • Urine protein:creatinine ratio (UPC) =\< 45 mg/mmol
  • Total =\< 1.5 x upper limit of normal (ULN); except in case of Gilbert's disease
  • (AST)/alanine aminotransferase (ALT) =\< 2.5 x ULN
  • Sodium, potassium, total calcium (corrected for serum albumin) \& phosphorus within normal limits per institutional guidelines
  • QTcF \< 450 msec (QT calculated using Fridericia formula)
  • Mean resting heart rate (determined from EKG) 50-100 beats per minute (BMP) (must be obtained from 12-lead EKG defined by a triplicate EKG for patients assigned to the capivasertib arm; patients assigned to all other arms will require a single EKG
  • No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or pre-existing Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)
  • ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Hemoglobin >= 8 g/dL

    * Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must not begin earlier than the day after the erythrocyte transfusion

  • ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: Prior Treatment

    • Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] grade =\< 1) from the acute effects of chemotherapy except for residual alopecia or grade 2 peripheral neuropathy prior to registration; a of at least 28 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy)
    • Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy; a washout period of at least 28 days is required between end of radiotherapy and registration
  • ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No active bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]); screening is not required for enrollment in the absence of symptoms
  • ADDITIONAL REGISTRATION ELIGIBILITY CRITERIA FOR ABEMACICLIB ARM: No personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
Terms in these criteria, in plain language(32)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
124 participants (estimated)

Study arms

  • Experimental
    Arm A (vismodegib)

    Patients receive vismodegib PO QD. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL FEBRUARY 2018)

    Drug: Vismodegib

  • Experimental
    Arm B (FAK inhibitor GSK2256098)

    Patients receive FAK inhibitor GSK2256098 PO BID. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. (CLOSED TO ACCRUAL JULY 2017)

    Drug: FAK Inhibitor GSK2256098

  • Experimental
    Arm C (capivasertib)

    Patients receive capivasertib PO BID on days 1-4. Treatment repeats every 7 days for up to 1 cycle (28 days) in the absence of disease progression or unacceptable toxicity.

    Drug: Capivasertib

  • Experimental
    Arm D (abemaciclib)

    Patients receive abemaciclib PO Q12H. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Drug: Abemaciclib

Interventions

06

What researchers measure

Primary outcomes

  1. Progression free survival (PFS)

    Point estimates and 95% binomial confidence intervals will be generated for the six month PFS rate within each cohort of each treatment arm. Kaplan-Meier curves will be generated for PFS for each cohort within each treatment arm.

    Time frame: At 6 months

  2. Response rate defined as a confirmed complete response (CR) or partial response (PR)

    Point estimates will be generated for response rates within each treatment arm with corresponding 95% binomial confidence intervals.

    Time frame: Up to 2 years

Secondary outcomes

  1. Overall survival (OS)

    OS will be summarized for each cohort within each treatment group with Kaplan-Meier curves and estimates.

    Time frame: Up to 2 years

  2. Incidence of adverse events according to National Cancer Institute CTCAE version 4.0

    Adverse events (AEs) will be summarized for each treatment group. They will be summarized as the number and frequency of each event. In addition the AEs will be summarized as the number and frequency of patients who experience any AE, AEs of grade 3+, and AEs of grade 4+.

    Time frame: Up to 4 weeks after completion of study treatment

07

Study locations

478 of 791 sites recruiting

Showing the first 100 of 791 sites. Choose a country and city above to see the rest.

08

References and documents

Publications

  • Brastianos PK, Dooley K, Geyer S, Gerstner ER, Kaufmann TJ, Iafrate AJ, Martinez-Lage M, Milhem M, Welch MR, Kaley TJ, Drappatz J, Chan A, Kumthekar P, Matsuoka CK, Strowd RE, Cohen AL, Jaeckle K, Robell L, Magge RS, Nam JY, Blondin N, Shaikh N, Rabinowitz I, Thomas AA, Piccioni DE, Brown P, Kaluziak S, Codd E, Cahill DP, Santagata S, Barker FG 2nd, Galanis E. Abemaciclib in meningiomas with somatic NF2 or CDK pathway alterations: the phase 2 Alliance A071401 trial. Nat Med. 2026 Feb;32(2):717-724. doi: 10.1038/s41591-025-04141-4. Epub 2026 Jan 16. PubMed 41545592 ↗
  • Brastianos PK, Twohy EL, Gerstner ER, Kaufmann TJ, Iafrate AJ, Lennerz J, Jeyapalan S, Piccioni DE, Monga V, Fadul CE, Schiff D, Taylor JW, Chowdhary SA, Bettegowda C, Ansstas G, De La Fuente M, Anderson MD, Shonka N, Damek D, Carrillo J, Kunschner-Ronan LJ, Chaudhary R, Jaeckle KA, Senecal FM, Kaley T, Morrison T, Thomas AA, Welch MR, Iwamoto F, Cachia D, Cohen AL, Vora S, Knopp M, Dunn IF, Kumthekar P, Sarkaria J, Geyer S, Carrero XW, Martinez-Lage M, Cahill DP, Brown PD, Giannini C, Santagata S, Barker FG 2nd, Galanis E. Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations. J Clin Oncol. 2023 Jan 20;41(3):618-628. doi: 10.1200/JCO.21.02371. Epub 2022 Oct 26. PubMed 36288512 ↗
09

Timeline

3 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2015 (actual). Primary completion is estimated for Jun 2028, 152 months after the start.

Of 37 phase 2 interventional studies under Meningioma, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 108. This study's planned 152 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 19, 2026: primary completion Jan 2027 → Jun 2028 and completion Jan 2028 → Jun 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 11, 2015
First posted
Aug 14, 2015
StartActual
Sep 28, 2015
Primary completionEst.
Jun 1, 2028was Jan 2027
CompletionEst.
Jun 1, 2029was Jan 2028
Last update
Nov 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
10 sites added, 2 sites removed. 34 sites changed recruiting status (28 now recruiting, 4 now suspended, …)
Show 34 sites
  • Northwestern University · Chicago, United StatesSuspended→Recruiting
  • Northwestern Medicine Cancer Center Delnor · Geneva, United StatesSuspended→Recruiting
  • Northwestern Medicine Orland Park · Orland Park, United StatesSuspended→Recruiting
  • Northwestern Medicine Cancer Center Warrenville · Warrenville, United StatesSuspended→Recruiting
  • Greater Regional Medical Center · Creston, United StatesRecruiting→Active, not recruiting
  • Trinity Health Muskegon Hospital · Muskegon, United StatesRecruiting→Suspended
  • Glens Falls Hospital · Glens Falls, United StatesSuspended→Recruiting
  • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
  • Sutter Auburn Faith Hospital · Auburn, United StatesActive, not recruiting→Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United StatesActive, not recruiting→Recruiting
  • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United StatesActive, not recruiting→Recruiting
  • Mills-Peninsula Medical Center · Burlingame, United StatesActive, not recruiting→Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United StatesActive, not recruiting→Recruiting
  • Eden Hospital Medical Center · Castro Valley, United StatesActive, not recruiting→Recruiting
  • Sutter Davis Hospital · Davis, United StatesActive, not recruiting→Recruiting
  • Palo Alto Medical Foundation-Fremont · Fremont, United StatesActive, not recruiting→Recruiting
  • Memorial Medical Center · Modesto, United StatesActive, not recruiting→Recruiting
  • Palo Alto Medical Foundation-Camino Division · Mountain View, United StatesActive, not recruiting→Recruiting
  • Palo Alto Medical Foundation-Gynecologic Oncology · Mountain View, United StatesActive, not recruiting→Recruiting
  • Sutter Cancer Research Consortium · Novato, United StatesActive, not recruiting→Recruiting
  • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesSuspended→Recruiting
  • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesActive, not recruiting→Recruiting
  • Sutter Cancer Centers Radiation Oncology Services-Roseville · Roseville, United StatesActive, not recruiting→Recruiting
  • Sutter Roseville Medical Center · Roseville, United StatesActive, not recruiting→Recruiting
  • Sutter Medical Center Sacramento · Sacramento, United StatesActive, not recruiting→Recruiting
  • California Pacific Medical Center-Pacific Campus · San Francisco, United StatesActive, not recruiting→Recruiting
  • Mills Health Center · San Mateo, United StatesActive, not recruiting→Recruiting
  • Palo Alto Medical Foundation-Santa Cruz · Santa Cruz, United StatesActive, not recruiting→Recruiting
  • Sutter Pacific Medical Foundation · Santa Rosa, United StatesActive, not recruiting→Recruiting
  • Palo Alto Medical Foundation-Sunnyvale · Sunnyvale, United StatesActive, not recruiting→Recruiting
  • …and 4 more on the registry record
Show 10 added (10 United States)
  • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
  • Sutter Health at SMSHCC · Oakland, United States
  • Ridley-Tree Cancer Center · Santa Barbara, United States
  • Dominican Santa Cruz Hospital · Santa Cruz, United States
  • Santa Cruz Radiation Oncology Medical Group · Santa Cruz, United States
  • Stockton Hematology Oncology Medical Group · Stockton, United States
  • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
  • Fairview Cancer Center - Woodbury · Woodbury, United States
  • Saint Anne Hospital · Burien, United States
  • Providence Swedish Cancer Institute · Everett, United States
Show 2 removed
  • Newland Medical Associates-Pontiac · Pontiac, United States
  • Highline Medical Center-Main Campus · Burien, United States
across 2 updates, Oct 2, 2026 – Nov 3, 2026
Primary completion
Jan 1, 2027→Jun 1, 2028
Oct 19, 2026
Study completion
Jan 2028→Jun 1, 2029
Oct 19, 2026
Site contacts
Changed at 150 sites. See the sites
Show 150 sites
  • Anchorage Associates in Radiation Medicine · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Alaska Breast Care and Surgery LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Alaska Oncology and Hematology LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Alaska Women's Cancer Care · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Katmai Oncology Group · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Providence Alaska Medical Center · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
  • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesContact added N•••@providence.org · •••4793Contact added (no phone or email listed)
  • Saint Luke's Cancer Institute - Boise · Boise, United StatesContact added e•••@slhs.org · •••2774Contact added (no phone or email listed)
  • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesContact added e•••@slhs.org · •••2774Contact added (no phone or email listed)
  • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesContact added e•••@slhs.org · •••2774Contact added (no phone or email listed)
  • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesContact added e•••@slhs.org · •••2774Contact added (no phone or email listed)
  • Saint Luke's Cancer Institute - Twin Falls · Twin Falls, United StatesContact added e•••@slhs.org · •••2774Contact added (no phone or email listed)
  • Northwestern University · Chicago, United StatesContact added c•••@northwestern.edu · •••1301Contact added (no phone or email listed)
  • Northwestern Medicine Cancer Center Delnor · Geneva, United StatesContact added D•••@nm.org · •••5360Contact added (no phone or email listed)
  • Northwestern Medicine Orland Park · Orland Park, United StatesContact added n•••@northwestern.eduContact added (no phone or email listed)
  • Northwestern Medicine Cancer Center Warrenville · Warrenville, United StatesContact added D•••@nm.org · •••5360Contact added (no phone or email listed)
  • Greater Regional Medical Center · Creston, United StatesContact removed •••3305Contact removed (no phone or email listed)
  • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesContact added c•••@crcwm.org · •••1230Contact added (no phone or email listed)
  • Beacon Kalamazoo Cancer Center · Kalamazoo, United StatesContact added •••7370Contact added (no phone or email listed)
  • Beacon Kalamazoo · Kalamazoo, United StatesContact added •••7370Contact added (no phone or email listed)
  • Trinity Health Muskegon Hospital · Muskegon, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
  • Saint Patrick Hospital - Community Hospital · Missoula, United StatesContact added a•••@providence.org · •••3118Contact added (no phone or email listed)
  • Glens Falls Hospital · Glens Falls, United StatesContact added •••6700Contact added (no phone or email listed)
  • Saint Charles Health System · Bend, United StatesContact added n•••@stcharleshealthcare.org · •••2909Contact added (no phone or email listed)
  • Clackamas Radiation Oncology Center · Clackamas, United StatesContact person changed (no phone or email listed)
  • Bay Area Hospital · Coos Bay, United StatesContact removed c•••@bayareahospital.org · •••8392Contact removed (no phone or email listed)
  • Providence Hood River Memorial Hospital · Hood River, United StatesContact added c•••@provdience.org · •••1979Contact added (no phone or email listed)
  • Providence Newberg Medical Center · Newberg, United StatesContact person changed (no phone or email listed)
  • Providence Willamette Falls Medical Center · Oregon City, United StatesContact person changed (no phone or email listed)
  • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
  • …and 120 more sites
across 2 updates, Oct 2, 2026 – Nov 3, 2026
Show all 3 updates
  1. Nov 3, 2026
    9 sites added, 2 sites removed. 65 sites changed recruiting status (61 now recruiting, 2 now active, not recruiting, …)
    Show 65 sites
    • Anchorage Associates in Radiation Medicine · Anchorage, United StatesSuspended→Recruiting
    • Alaska Breast Care and Surgery LLC · Anchorage, United StatesSuspended→Recruiting
    • Alaska Oncology and Hematology LLC · Anchorage, United StatesSuspended→Recruiting
    • Alaska Women's Cancer Care · Anchorage, United StatesSuspended→Recruiting
    • Katmai Oncology Group · Anchorage, United StatesSuspended→Recruiting
    • Providence Alaska Medical Center · Anchorage, United StatesSuspended→Recruiting
    • Sutter Auburn Faith Hospital · Auburn, United StatesActive, not recruiting→Recruiting
    • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United StatesActive, not recruiting→Recruiting
    • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United StatesActive, not recruiting→Recruiting
    • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesSuspended→Recruiting
    • Mills-Peninsula Medical Center · Burlingame, United StatesActive, not recruiting→Recruiting
    • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United StatesActive, not recruiting→Recruiting
    • Eden Hospital Medical Center · Castro Valley, United StatesActive, not recruiting→Recruiting
    • Sutter Davis Hospital · Davis, United StatesActive, not recruiting→Recruiting
    • Palo Alto Medical Foundation-Fremont · Fremont, United StatesActive, not recruiting→Recruiting
    • Memorial Medical Center · Modesto, United StatesActive, not recruiting→Recruiting
    • Palo Alto Medical Foundation-Camino Division · Mountain View, United StatesActive, not recruiting→Recruiting
    • Palo Alto Medical Foundation-Gynecologic Oncology · Mountain View, United StatesActive, not recruiting→Recruiting
    • Sutter Cancer Research Consortium · Novato, United StatesActive, not recruiting→Recruiting
    • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesSuspended→Recruiting
    • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesActive, not recruiting→Recruiting
    • Sutter Cancer Centers Radiation Oncology Services-Roseville · Roseville, United StatesActive, not recruiting→Recruiting
    • Sutter Roseville Medical Center · Roseville, United StatesActive, not recruiting→Recruiting
    • Sutter Medical Center Sacramento · Sacramento, United StatesActive, not recruiting→Recruiting
    • California Pacific Medical Center-Pacific Campus · San Francisco, United StatesActive, not recruiting→Recruiting
    • Mills Health Center · San Mateo, United StatesActive, not recruiting→Recruiting
    • Palo Alto Medical Foundation-Santa Cruz · Santa Cruz, United StatesActive, not recruiting→Recruiting
    • Sutter Pacific Medical Foundation · Santa Rosa, United StatesActive, not recruiting→Recruiting
    • Palo Alto Medical Foundation-Sunnyvale · Sunnyvale, United StatesActive, not recruiting→Recruiting
    • Sutter Solano Medical Center/Cancer Center · Vallejo, United StatesActive, not recruiting→Recruiting
    • …and 35 more on the registry record
    Show 9 added (9 United States)
    • Sutter Health at SMSHCC · Oakland, United States
    • Ridley-Tree Cancer Center · Santa Barbara, United States
    • Dominican Santa Cruz Hospital · Santa Cruz, United States
    • Santa Cruz Radiation Oncology Medical Group · Santa Cruz, United States
    • Stockton Hematology Oncology Medical Group · Stockton, United States
    • Trinity Health IHA Medical Group-Alice Gustafson Center · Pontiac, United States
    • Fairview Cancer Center - Woodbury · Woodbury, United States
    • Saint Anne Hospital · Burien, United States
    • Providence Swedish Cancer Institute · Everett, United States
    Show 2 removed
    • Newland Medical Associates-Pontiac · Pontiac, United States
    • Highline Medical Center-Main Campus · Burien, United States
    Site contacts Changed at 139 sites. See the sites
    Show 139 sites
    • Anchorage Associates in Radiation Medicine · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Alaska Breast Care and Surgery LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Alaska Oncology and Hematology LLC · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Alaska Women's Cancer Care · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Katmai Oncology Group · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Providence Alaska Medical Center · Anchorage, United StatesContact added A•••@providence.org · •••6871Contact added (no phone or email listed)
    • Kingman Regional Medical Center · Kingman, United StatesContact person changed (no phone or email listed)
    • Cancer Center at Saint Joseph's · Phoenix, United StatesContact person changed (no phone or email listed)
    • Mission Hope Medical Oncology - Arroyo Grande · Arroyo Grande, United StatesContact person changed (no phone or email listed)
    • PCR Oncology · Arroyo Grande, United StatesContact person changed (no phone or email listed)
    • Sutter Auburn Faith Hospital · Auburn, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Cancer Centers Radiation Oncology Services-Auburn · Auburn, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Alta Bates Summit Medical Center-Herrick Campus · Berkeley, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesContact added N•••@providence.org · •••4793Contact added (no phone or email listed)
    • Mills-Peninsula Medical Center · Burlingame, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Cancer Centers Radiation Oncology Services-Cameron Park · Cameron Park, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Mercy Cancer Center - Carmichael · Carmichael, United StatesContact person changed (no phone or email listed)
    • Mercy San Juan Medical Center · Carmichael, United StatesContact person changed (no phone or email listed)
    • Eden Hospital Medical Center · Castro Valley, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Davis Hospital · Davis, United StatesContact added N•••@sutterhealth.orgContact added (no phone or email listed)
    • Mercy Cancer Center - Elk Grove · Elk Grove, United StatesContact person changed (no phone or email listed)
    • Palo Alto Medical Foundation-Fremont · Fremont, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Mercy Cancer Center · Merced, United StatesContact person changed (no phone or email listed)
    • Memorial Medical Center · Modesto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Palo Alto Medical Foundation-Camino Division · Mountain View, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Palo Alto Medical Foundation-Gynecologic Oncology · Mountain View, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Sutter Cancer Research Consortium · Novato, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • UC Irvine Health/Chao Family Comprehensive Cancer Center · Orange, United StatesContact added u•••@uci.edu · •••8839Contact added (no phone or email listed)
    • Palo Alto Medical Foundation Health Care · Palo Alto, United StatesContact added c•••@sutterhealth.orgContact added (no phone or email listed)
    • Mercy Cancer Center - Rocklin · Rocklin, United StatesContact person changed (no phone or email listed)
    • …and 109 more sites
    + 1 other change: verification date
  2. Oct 19, 2026
    Primary completion Jan 1, 2027→Jun 1, 2028
    Study completion Jan 2028→Jun 1, 2029
  3. Oct 2, 2026
    1 site added. 46 sites changed recruiting status (41 now suspended, 5 now recruiting)
    Show 46 sites
    • Anchorage Associates in Radiation Medicine · Anchorage, United StatesRecruiting→Suspended
    • Alaska Breast Care and Surgery LLC · Anchorage, United StatesRecruiting→Suspended
    • Alaska Oncology and Hematology LLC · Anchorage, United StatesRecruiting→Suspended
    • Alaska Women's Cancer Care · Anchorage, United StatesRecruiting→Suspended
    • Katmai Oncology Group · Anchorage, United StatesRecruiting→Suspended
    • Providence Alaska Medical Center · Anchorage, United StatesRecruiting→Suspended
    • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Boise · Boise, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesRecruiting→Suspended
    • Saint Luke's Cancer Institute - Twin Falls · Twin Falls, United StatesRecruiting→Suspended
    • Northwestern University · Chicago, United StatesSuspended→Recruiting
    • Northwestern Medicine Cancer Center Delnor · Geneva, United StatesSuspended→Recruiting
    • Northwestern Medicine Orland Park · Orland Park, United StatesSuspended→Recruiting
    • Northwestern Medicine Cancer Center Warrenville · Warrenville, United StatesSuspended→Recruiting
    • Greater Regional Medical Center · Creston, United StatesRecruiting→Suspended
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesRecruiting→Suspended
    • Beacon Kalamazoo Cancer Center · Kalamazoo, United StatesRecruiting→Suspended
    • Beacon Kalamazoo · Kalamazoo, United StatesRecruiting→Suspended
    • Trinity Health Muskegon Hospital · Muskegon, United StatesRecruiting→Suspended
    • Saint Patrick Hospital - Community Hospital · Missoula, United StatesRecruiting→Suspended
    • Glens Falls Hospital · Glens Falls, United StatesSuspended→Recruiting
    • Saint Charles Health System · Bend, United StatesRecruiting→Suspended
    • Bay Area Hospital · Coos Bay, United StatesRecruiting→Suspended
    • Providence Hood River Memorial Hospital · Hood River, United StatesRecruiting→Suspended
    • Saint Charles Health System-Redmond · Redmond, United StatesRecruiting→Suspended
    • Providence Regional Cancer System-Aberdeen · Aberdeen, United StatesRecruiting→Suspended
    • PeaceHealth Saint Joseph Medical Center · Bellingham, United StatesRecruiting→Suspended
    • Providence Regional Cancer System-Centralia · Centralia, United StatesRecruiting→Suspended
    • …and 16 more on the registry record
    Show site
    • Trinity Health IHA Medical Group - Primary Care - Clarkston · Clarkston, United States
    Site contacts Changed at 54 sites. See the sites
    Show 54 sites
    • Anchorage Associates in Radiation Medicine · Anchorage, United StatesContact removed A•••@providence.org · •••6871Contact removed (no phone or email listed)
    • Alaska Breast Care and Surgery LLC · Anchorage, United StatesContact removed A•••@providence.org · •••6871Contact removed (no phone or email listed)
    • Alaska Oncology and Hematology LLC · Anchorage, United StatesContact removed A•••@providence.org · •••6871Contact removed (no phone or email listed)
    • Alaska Women's Cancer Care · Anchorage, United StatesContact removed A•••@providence.org · •••6871Contact removed (no phone or email listed)
    • Katmai Oncology Group · Anchorage, United StatesContact removed A•••@providence.org · •••6871Contact removed (no phone or email listed)
    • Providence Alaska Medical Center · Anchorage, United StatesContact removed A•••@providence.org · •••6871Contact removed (no phone or email listed)
    • Providence Saint Joseph Medical Center/Disney Family Cancer Center · Burbank, United StatesContact removed N•••@providence.org · •••4793Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Boise · Boise, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Fruitland · Fruitland, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Meridian · Meridian, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Nampa · Nampa, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Saint Luke's Cancer Institute - Twin Falls · Twin Falls, United StatesContact removed e•••@slhs.org · •••2774Contact removed (no phone or email listed)
    • Northwestern University · Chicago, United StatesContact added c•••@northwestern.edu · •••1301Contact added (no phone or email listed)
    • Northwestern Medicine Cancer Center Delnor · Geneva, United StatesContact added D•••@nm.org · •••5360Contact added (no phone or email listed)
    • Northwestern Medicine Orland Park · Orland Park, United StatesContact added n•••@northwestern.eduContact added (no phone or email listed)
    • Northwestern Medicine Cancer Center Warrenville · Warrenville, United StatesContact added D•••@nm.org · •••5360Contact added (no phone or email listed)
    • Greater Regional Medical Center · Creston, United StatesContact removed •••3305Contact removed (no phone or email listed)
    • Trinity Health Grand Rapids Hospital · Grand Rapids, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
    • Beacon Kalamazoo Cancer Center · Kalamazoo, United StatesContact removed •••7370Contact removed (no phone or email listed)
    • Beacon Kalamazoo · Kalamazoo, United StatesContact removed •••7370Contact removed (no phone or email listed)
    • Trinity Health Muskegon Hospital · Muskegon, United StatesContact removed c•••@crcwm.org · •••1230Contact removed (no phone or email listed)
    • Saint Patrick Hospital - Community Hospital · Missoula, United StatesContact removed a•••@providence.org · •••3118Contact removed (no phone or email listed)
    • Glens Falls Hospital · Glens Falls, United StatesContact added •••6700Contact added (no phone or email listed)
    • Saint Charles Health System · Bend, United StatesContact removed n•••@stcharleshealthcare.org · •••2909Contact removed (no phone or email listed)
    • Clackamas Radiation Oncology Center · Clackamas, United StatesContact person changed (no phone or email listed)
    • Bay Area Hospital · Coos Bay, United StatesContact removed c•••@bayareahospital.org · •••8392Contact removed (no phone or email listed)
    • Providence Hood River Memorial Hospital · Hood River, United StatesContact removed c•••@provdience.org · •••1979Contact removed (no phone or email listed)
    • Providence Newberg Medical Center · Newberg, United StatesContact person changed (no phone or email listed)
    • Providence Willamette Falls Medical Center · Oregon City, United StatesContact person changed (no phone or email listed)
    • Providence Portland Medical Center · Portland, United StatesContact person changed (no phone or email listed)
    • …and 24 more sites
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT02523014
Collaborators
National Cancer Institute (NCI), GlaxoSmithKline, Genentech, Inc., Brain Science Foundation
Responsible party
Sponsor
First posted
Aug 14, 2015
Start date
Sep 28, 2015
Primary completion
Jun 1, 2028 (estimated)
Completion
Jun 1, 2029 (estimated)
Last update
Nov 3, 2026

Study contacts

Priscilla Brastianos, MD
Contact
617-643-1939
Priscilla Brastianos, MD
study chair · Massachusetts General Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: HhAntag691 · GSK2256098 · Capivasertib · Abemaciclib

Start the discussion